Eli Lil­ly scores ex­pand­ed MACE la­bel for Trulic­i­ty; Gilead­'s CAR-T Yescar­ta gets in Chi­na re­view line

→ The FDA has ex­pand­ed the la­bel for Eli Lil­ly‘s type 2 di­a­betes drug Trulic­i­ty, say­ing that it is now ap­proved to low­er the risk of a ma­jor ad­verse car­diac event. The ex­pand­ed ap­proval comes af­ter a near­ly decade-long tri­al of near­ly 10,000 pa­tients on Trulic­i­ty or place­bo showed that the drug slight­ly low­ered the risk of car­dio­vas­cu­lar death, non­fa­tal heart at­tack and non­fa­tal stroke. Trulic­ty is a GLP-1 ag­o­nist, mean­ing it in­creas­es in­sulin se­cre­tion and re­duces glucagon se­cre­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.